Sandoz Canada launched a digital campaign to provide fact-based materials on biosimilars in hopes of spreading awareness on the benefits of biosimilars for physicians and patients.
Sandoz Canada launched The Biosimilars Generation, an online campaign that provides fact-based information about biosimilar medicines in Canada for patients and physicians to access.
Sandoz created the resource to increase awareness for Canadians on the benefits, safety, efficacy, and savings opportunities biosimilar drugs can provide.
“Biologic medicines have transformed the treatment of many complex diseases; however, the cost of these medicines is also putting financial strain on our healthcare system, now even under more pressure due to the coronavirus pandemic. We are committed to increasing patient access to biosimilar medicines that can help alleviate this budget pressure,” said Michel Robidoux, president and general manager of Sandoz Canada.
The Biosimilars Generation serves as a directory where visitors can learn about all things biosimilars and can search for information on biosimilar programs and formularies by province.
This effort comes in response to an increasing number of Canadian provinces beginning to implement switching programs for biosimilars. Biosimilar transition programs have already seen success in British Columbia and Alberta, with 4 other provinces including Ontario and Manitoba looking to implement their own.
“There is an increasing demand for credible, fact-based information from Canadians looking to learn more about the safety, efficacy and value of biosimilar medicines….The Biosimilars Generation… shows that we are all in it together, to be informed, empowered and supported,” Karine Matteau, vice president of hospitals and physicians channel and head of biopharmaceuticals at Sandoz Canada, said in a statement.
An Expert’s Reaction
“I was pretty impressed about how generic it was because it’s really hard to tell that they were talking about Sandoz except that, obviously, Sandoz came out with it,” said Carter Thorne, MD, an assistant professor at the University of Toronto and chief of the Division of Rheumatology and director of The Arthritis Program at Southlake Regional health Centre in Newmarket, Ontario, in an interview with The Center for Biosimilars®.
Thorne added that he thought the site showed the long-term commitment that Sandoz has for the development and marketing of biosimilar products.
“If I was to send a patient that indicated an interest in looking at a very reliable looking or truthful looking site, I’d send them to [The Biosimilar Generation]. The stuff I read was all very straightforward. It was all things I believed or understood,” said Thorne.
Thorne also praised Sandoz’ attention to providing information on the different regulatory systems regarding each province, which is helpful as misconceptions about Canada’s health care system can cause confusion for the public.
“It is a pretty balanced thing, and I thought if I had to criticize, perhaps I’d say it was a bit too high end in terms of information," he noted. "It wasn’t the grade 6 or grade 8 education that [companies] usually think about for tools that are made for the population. But having said that, I thought it was really nicely done and nicely laid out.”
Canada’s Fight for Biosimilar Adoption
Canada, similar to the United States, has been slow to embrace biosimilars despite evidence demonstrating that approved biosimilars are as safe and effective as their reference products.
In March 2020, Canadian investigators concluded that more systematic efforts needed to be taken to achieve widespread adoption of biosimilars in clinical practice as poor adoption rates without concurrent education and clear understanding of biosimilars can exist anywhere where biosimilars are available.
In 2019, the pan-Canadian Pharmaceutical Alliance (pCPA) engaged the Canadian Agency for Drugs and Technologies in Health (CADTH) to lead a multiphase stakeholder consultation process that aimed to ensure stakeholders perspectives about biosimilars could be captured and conveyed to policymakers and encourage biosimilar uptake.
In 2017, another stakeholder initiative took place between pCPA and Cancer Care Ontario to ensure the implementation and use of therapeutic oncology biosimilars were appropriate and cost-effective across Canada.
The pCPA also published a document in 2018 with the goal of developing a clear and consistent pan-Canadian approach to across Canada for reference products and biosimilars.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.